Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
36 hedge funds and large institutions have $7.51M invested in Oncternal Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.
8% less funds holding
Funds holding: 39 → 36 (-3)
29% less capital invested
Capital invested by funds: $10.6M → $7.51M (-$3.06M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$216K |
| 2 |
DT
Diversified Trust
Memphis,
Tennessee
|
+$20.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$4.33K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$44K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$29.5K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$15K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14K |
| 5 |
Morgan Stanley
New York
|
-$13K |
ONCT Hedge Fund Activity: Q1 2016 in Review
36 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2016, worth a combined $7.51M — down 29% from $10.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ONCT and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was BVF Inc, adding an estimated $216K. The largest seller was Spark Investment Management, exiting entirely with an estimated $44K sold.
- 36 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2016, down from 39 in Q4 2015.
- Funds reported $7.51M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2016, down 29% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2016 and 6 closed out, a net change of -3 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2016 was BVF Inc, an estimated $216K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2016 was Spark Investment Management, an estimated $44K sold.
Based on aggregated 13F filings for Q1 2016.